KEYTRUDA 25 mg/mL concentrate for solution for infusion, ADSTILADRIN, GEMCITABINE , DOCETAXEL
000434
Phase 3 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, ADSTILADRIN, GEMCITABINE , DOCETAXEL for High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours is a Phase 3 program (small_molecule) at Ferring Pharmaceuticals A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ferring Pharmaceuticals A/S
- Indication
- High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ(CIS) with or without papillary tumours
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active